First-Line VT Ablation: Trials, Tools & Timing: EP Edge Newsletter June 2025

The paradigm is shifting. Ventricular tachycardia (VT) ablation is stepping out of the shadows—from rescue therapy to first-line strategy, driven by landmark trials like VANISH2, PAUSE-SCD, and PARTITA. Meanwhile, pulse field ablation (PFA) continues its rapid evolution—crossing over from atrial to ventricular applications—but questions about durability and embolic safety persist.In this episode of EP Edge, Dr. Niraj Sharma takes you through the key data shaping modern electrophysiology, from trial outcomes to emerging technology, including injectable light-activated pacemakers and telomere-targeting strategies that may redefine longevity and prevention.Whether you’re an EP, a general cardiologist, or in allied research, this episode offers evidence-based insights and forward-looking perspectives on where rhythm science is heading.For: Source data/infographics see EPEDGE Newsletter on LinkedInFor feedback, collaborations, or questions, email Dr. Niraj Sharma at [email protected] connect on LinkedIn

There are no comments yet.

Please log in to write the first comment.